Absolute and Relative Risks of Kidney and Urological Complications in Patients With Inflammatory Bowel Disease
Authors:
- 10 August 2023
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (1) , 138-146
Abstract
INTRODUCTION: The burden of kidney and urological complications in patients with inflammatory bowel disease (IBD) remains poorly characterized. METHODS: We analyzed association between developing IBD (as a time-varying exposure) and relative risks of receiving diagnoses of chronic kidney disease (CKD), acute kidney injury (AKI), or kidney stones, and experiencing a clinically-relevant decline in estimated glomerular filtration rate (eGFR) (CKD progression; composite of kidney failure or an eGFR decline ≥30%) in 1,682,795 individuals seeking healthcare in Stockholm, Sweden, during 2006–2018. We quantified 5- and 10-year absolute risks of these complications in a parallel matched cohort of IBD cases and random controls matched (1:5) on sex, age, and eGFR. RESULTS: During median 9 years, 10,117 participants developed IBD. Incident IBD was associated with higher risks of kidney-related complications compared with non-IBD periods: hazard ratio (HR) (95% confidence interval) was 1.24 (1.10–1.40) for receiving a CKD diagnosis and 1.11 (1.00–1.24) for CKD progression. For absolute risks, 11.8% IBD cases had a CKD event within 10-year. Of these, 6.4% received a CKD diagnosis, and 7.9% reached CKD progression. The risks of AKI (HR 1.97 [1.70–2.29]; 10-year absolute risk 3.6%) and kidney stones (HR 1.69 [1.48–1.93]; 10-year absolute risk 5.6%) were also elevated. Risks were similar in Crohn's disease and ulcerative colitis. DISCUSSION: More than 10% of patients with IBD developed CKD within 10-year from diagnosis, with many not being identified through diagnostic codes. This, together with their elevated AKI and kidney stone risks, highlights the need of established protocols for kidney function monitoring and referral to nephrological/urological care for patients with IBD.Keywords
Funding Information
- Vetenskapsrådet (2019-01059)
- Martin Rinds Stiftelse
- Vetenskapsrådet
- Stockholms Läns Landsting
- Karolinska Institutet
This publication has 45 references indexed in Scilit:
- Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Renal manifestations and complications of inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An UpdateAmerican Journal of Kidney Diseases, 2009
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- 5-Aminosalicylates and renal function in inflammatory bowel diseaseInflammatory Bowel Diseases, 2007
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Neyman's bias re-visitedJournal of Clinical Epidemiology, 2003
- Urine stone risk factors in nephrolithiasis patients with and without bowel diseaseKidney International, 2003
- Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2000
- Amyloidosis and Inflammatory Bowel Disease A 50-Year Experience with 25 PatientsMedicine, 1992